Peptide-Phospholipid Conjugates for CD36 Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the CD36 macrophage receptor for atherosclerosis treatment are unstable and lack specificity, leading to ineffective inhibition of oxidized low-density lipoprotein (OxLDL) uptake by macrophages.
Innovation Solution
Development of stable peptide-phospholipid conjugates that specifically bind to the CD36 receptor, inhibiting OxLDL uptake and formulated for pharmaceutical use in treating or preventing atherosclerosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Schiff's base conjugates or amine adducts are used to target CD36 receptor, then binding activity is achieved, but stability in aqueous solution deteriorates due to hydrolysis or intramolecular O-N-acyl transfer
Solution Approach 1:
The patent introduces a stable peptide-phospholipid conjugate structure as an intermediary that maintains the essential binding features of OxLDL (phosphorylcholine head group and sn-2 acyl chain) while eliminating the instability of Schiff's bases and amine adducts. The conjugate uses a stable amide bond formed between the phospholipid carboxyl group and peptide amine group, preventing hydrolysis and intramolecular O-N-acyl transfer that plague earlier compounds.
Solution Approach 2:
The invention creates a composite molecule combining phospholipid and peptide components into a stable conjugate structure. This composite approach allows the molecule to exhibit both the CD36-binding properties of phospholipids and the stability of peptide-amide bonds, resolving the contradiction between binding activity and aqueous stability.
2Reliability
If conventional compounds are used to inhibit OxLDL uptake, then some binding activity is achieved, but specificity for CD36 receptor deteriorates leading to ineffective inhibition
Solution Approach 1:
The patent applies local quality by precisely positioning specific structural features at critical locations: the phosphorylcholine head group at the binding interface for CD36 recognition, and the sn-2 acyl chain in the correct orientation for receptor interaction. This localized optimization ensures high specificity for CD36 while maintaining binding activity, preventing off-target effects.
3Productivity
If unstable compounds are used for treatment, then some therapeutic effect is achieved, but effectiveness deteriorates due to decomposition before reaching target
Solution Approach 1:
The invention changes the chemical parameters of the compound by replacing labile imine bonds with stable amide bonds in the peptide-phospholipid conjugate structure. This parameter change dramatically improves aqueous stability and in vivo half-life while preserving the therapeutic effect of CD36-mediated OxLDL inhibition, allowing the compound to reach and act at the target site effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-phospholipid conjugates demonstrate strong, specific binding to the CD36 receptor, effectively competing with OxLDL for macrophage binding, providing a stable and effective treatment for atherosclerosis.
Implementation Method 1
the phosphorylcholine head group is essential for binding to CD36 and for antigenicity for E06, but that this activity required prior conjugation of the sn-2 aldehyde with a peptide or protein to yield a Schiff's base
Implementation Method 2
The aqueous solution of the conjugate slowly lost its activity in the assay as the imine hydrolyzed
Implementation Method 3
the imine intermediate was reduced to the corresponding amine with sodium cyanoborohydride
Data Source
AI summary
The present invention provides a peptide-phospholipid conjugate of Formula 1:wherein: X is selected from the group consisting of —CR1R2—, —R3—, —O—, —S—, and S+(R3)—; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.